Keywords: Protalix, Pfizer, Elelyso, Financial milestone

$25 million milestone for Protalix following US approval of Elelyso

Article | 13 June 2012

Israel-based Protalix BioTherapeutics (TASE:PLX) has received a $25 million milestone payment from global pharma behemoth Pfizer (NYSE: PFE), which was ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Pfizer

Protalix BioTherapeutics

Go to company listing

Related Drugs

Elelyso

Go to drug listing